This ASX healthcare share has finally come back to earth.

4DMedical Ltd (ASX: 4DX) shares fell 7% to $4.10 during Wednesday’s session, extending a sharp pullback that has now left the stock about 46% below the record highs reached in April.

Before anyone panics, though, it’s worth zooming out. This ASX healthcare share is still up an astonishing 1,528% over the past 12 months. Yes, that’s more than fifteen-fold in a year.

But here’s the catch: 4DMedical isn’t a tiny speculative medical technology company anymore. With a market capitalisation of roughly $2.6 billion, investors are already betting on a business that becomes much, much larger.

So where does it go from here?

Solving a real problem

The story behind this ASX healthcare share isn’t just hype.

4DMedical has developed advanced respiratory imaging technology that shows how lungs actually function rather than simply what they look like.

Using proprietary software and artificial intelligence, its technology creates detailed functional images that can help doctors diagnose and monitor respiratory diseases far more effectively than traditional imaging.

That’s a powerful proposition in a world increasingly embracing AI-driven healthcare.

Company keeps expanding its opportunity

This ASX healthcare share hasn’t been sitting still. One of management’s biggest recent moves was acquiring Austrian imaging specialist Contextflow.

The deal immediately strengthened 4DMedical’s presence in Europe, added lung cancer screening capabilities and provided access to existing reimbursement pathways in Germany.

Management believes the acquisition expands its addressable market by around 50%. That’s no small upgrade. Instead of being an emerging Australian medical technology company, 4DMedical is steadily building the foundations of a global imaging business.

Major scalp in the US

The United States remains the biggest prize for this ASX healthcare share. Recently, the company signed a major agreement with SimonMed, one of America’s largest outpatient imaging providers with more than 170 imaging centres.

The partnership supports the rollout of 4DMedical’s CT:VQ lung imaging technology across a substantial healthcare network. Even more importantly, the company believes these initiatives could expand its US addressable market for CT:VQ to around US$3 billion.

If adoption continues gathering pace, that’s a very large runway.

Where to from here?

Success creates a funny problem. The better this ASX healthcare share performs, the higher the expectations become.

After last year’s extraordinary rally, investors are no longer rewarding exciting stories alone. They want evidence of growing revenue, expanding reimbursement coverage and increasing commercial adoption.

The Contextflow acquisition also needs to deliver on its promise.

Any slowdown in customer adoption or execution could trigger more volatility, particularly after such an enormous share price run.

The next chapter now depends less on headlines and more on execution. If 4DMedical continues converting clinical success into commercial wins, today’s speed bump could eventually look like just another pit stop on a much longer journey.

The post This red-hot ASX healthcare share hit a speed bump. What next? appeared first on The Motley Fool Australia.

More reading

• 13 ASX 200 shares that doubled in value in FY26
• 2 ASX 200 healthcare shares to buy after sector rebounds 23% in a month
• These are the 10 most shorted ASX shares
• Healthcare shares lead the ASX 200 again as sector rotation gathers pace
• ASX shares vs. property in FY26: Which investment outperformed?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Consumer staples shares have performed strongly in 2026 as investors have pushed towards defensive options.

The S&P/ASX 200 Consumer Staples Index (ASX: XSJ) has risen 13% year to date. 

This has far outpaced the S&P/ASX 200 Index (ASX: XJO), which is up just 0.66% in the same span. 

Despite the sector performing well, ASX consumer staples stock Select Harvests Ltd (ASX: SHV) is down significantly year to date. 

However, a new report from Bell Potter has indicated it could be set for a strong rebound. 

Company overview

Select Harvests is an integrated grower, processor and marketer of almonds, owning and operating farming and processing assets in Australia. 

It offers a vertically integrated model with core capabilities in farming, processing and marketing.

The company operates a diversified portfolio of almond orchards as well as a state-of-the-art processing facility in Carina VIC (with capacity to process 50,000t of almonds).

In 2026, the stock has fallen 20%, however Bell Potter’s latest guidance indicates it could recover in the next 12 months. 

Here’s what the broker had to say. 

Production maintained

Bell Potter said in yesterday’s report that the recent weakness in this ASX consumer staples stock is not supported by improving almond market fundamentals. 

Global almond prices have risen 11% year-on-year, while a weaker Australian dollar has lifted implied Californian almond prices to A$10.55-10.60/kg. 

This is above SHV’s 1H26 pricing assumption of A$10.21/kg.

Despite Select Harvest shares falling around 20% since the start of 2026, the company has maintained FY26 production guidance of 28,000–31,000 tonnes, which aligns with its expected theoretical production of around 29,000 tonnes. 

Bell Potter believes this suggests the market is overly focused on past operational issues rather than current fundamentals.

Taking into account the company’s foreign exchange hedge position, stronger-than-expected almond price trends, and benchmark market performance, Bell Potter sees upside risk to the company’s 1H26 almond price assumption. 

If current market prices persist, realised prices could be closer to A$10.50–10.60/kg, providing potential upside to earnings and the share price.

Strong upside in tact for consumer staples stock

Based on this guidance, Bell Potter has retained its buy recommendation and $5.30 price target. 

From current levels, this indicates an upside potential of 35%. 

SHV has had a series of disappointing results in recent years, however, the fundamental drivers of the business are improving – almond prices are rising, crop input prices (fertiliser and ag-chem) have weakened from the highs and forward year water lease coverage has improved.

The post Why this could be the best buy in the consumer staples sector right now: Expert  appeared first on The Motley Fool Australia.

More reading

• Why this ASX stock is a ‘compelling value play’
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Superannuation may be the best place to invest for passive income, thanks to the fact that the tax rate is so low compared to individual and company tax rates.

Superannuation investors could have a low tax rate in the accumulation phase and perhaps a 0% tax rate in the retirement phase.

When the income is taxed so little, it means investors’ after-tax income can be similar (or identical) to the before-tax income. It’s the after-tax income figure that investors should focus on, in my view.

If superannuation investors are after passive income, I think the following ideas are very compelling with $5,000 (or more).

Centuria Industrial REIT (ASX: CIP)

This is a real estate investment trust (REIT) that owns a portfolio of industrial properties across the country. These buildings are located across high-demand areas where vacancy is low.

With tailwinds like e-commerce adoption, refrigerated space, and data centres driving increased demand for industrial demand, this is a strong tailwind for rental income and supporting distributions.

In the first half of FY26, the business reported like-for-like net operating income (NOI) growth of 5.1%, which I think is a solid rate of growth for a REIT. It also noted that its portfolio’s rental income potential growth is strong, with an average under-renting of 20% of its real estate, suggesting a big rental increase when the contract comes up for renewal.

The business declared passive income of 16.8 cents per security in FY26, translating into a distribution yield of 5.6%. I think it’s a good time to invest while interest rates are higher because that’s a headwind for property values – this effect could reverse once interest rates start coming down again.

Plus, it’s trading at a large double-digit discount to its net tangible assets (NTA), which was reported as $3.95 per unit as of 31 December 2025.

MFF Capital Investments Ltd (ASX: MFF)

Another ASX share that looks like an excellent passive income buy for superannuation is the listed investment company (LIC) MFF. LICs are a great investment structure because they enable the board to declare the size of dividends they want, allowing for consistent, growing dividends.

MFF has a stated intention to increase dividend payments to investors, which I believe makes it an appealing pick for investors seeking payout stability (and growth).

Companies pay for dividends from the profit they make. MFF generates income by generating investment returns from a portfolio of high-quality international shares with strong economic moats.

If you’re going to invest in shares, why not own some of the best contenders that can deliver good compounding earnings, which is a key driver of shareholder returns?  Retained investment returns that aren’t paid out as dividends can help drive the MFF share price higher over time as the underlying value of the business – measured by the NTA – grows.

MFF intends to pay an annual dividend per share of 21 cents for FY26, translating into a grossed-up dividend yield of 5.8%, including franking credits.

The post How to invest $5,000 for passive income in superannuation? appeared first on The Motley Fool Australia.

More reading

• How should I invest my money in FY27?
• How much is needed in superannuation to target a $70,000 annual passive income?
• 148,572 shares of this high-yield ASX dividend stock pays an income equal to the Age Pension
• How much is needed in superannuation to target $60,000 in annual passive income?
• 3 of the best ASX dividend shares I own for passive income

Motley Fool contributor Tristan Harrison has positions in Mff Capital Investments. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Mff Capital Investments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.